Trial · NCT01549886
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
NCT01549886, Phase 2, Terminated, Spectrum Pharmaceuticals, Inc; results first posted 2021-10-04
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma. Trials, record NCT01549886. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01549886
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
- NCT number
- NCT01549886
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab
- First posted
- 2012-03-09
- Last updated
- 2021-10-04
- Results first posted
- 2021-10-04
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CR) | 6 Months | |
| Secondary | Overall Response Rate | 3 Months and 6 Months | Complete response rate within 3 months, overall response rate within 6 months and progression-free survival. |
| Secondary | Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | From time of dosing until 2 years | An Adverse Events (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Non-SAEs was an AE events that are not Serious Adverse Events. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Response Rate (CR) | 6 Months | Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons. | ||
| SECONDARY | Overall Response Rate | 3 Months and 6 Months | Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons. | ||
| SECONDARY | Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | From time of dosing until 2 years | Safety analysis population. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | MGD+Rituximab+Y-90-Zevalin | Serious Adverse Events | 1 | Participants | |
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Rituximab+Y-90-Zevalin | Serious Adverse Events | 2 | Participants | |
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | MGD+Rituximab+Y-90-Zevalin | Non-Serious Adverse Events | 2 | Participants | |
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Rituximab+Y-90-Zevalin | Non-Serious Adverse Events | 3 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MGD+Rituximab+Y-90-Zevalin | 2 | |
| Overall Study | STARTED | Rituximab+Y-90-Zevalin | 3 | |
| Overall Study | COMPLETED | MGD+Rituximab+Y-90-Zevalin | 0 | |
| Overall Study | COMPLETED | Rituximab+Y-90-Zevalin | 0 | |
| Overall Study | NOT COMPLETED | MGD+Rituximab+Y-90-Zevalin | 2 | |
| Overall Study | NOT COMPLETED | Rituximab+Y-90-Zevalin | 3 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Discomfort | Gastrointestinal disorders | MGD+Rituximab+Y-90-Zevalin | 2 | 2 | 2 |
| other | Abdominal Discomfort | Gastrointestinal disorders | Rituximab+Y-90-Zevalin | 0 | 3 | 0 |
| other | Neutrophils count decreased | Investigations | MGD+Rituximab+Y-90-Zevalin | 0 | 2 | 0 |
| other | Neutrophils count decreased | Investigations | Rituximab+Y-90-Zevalin | 3 | 3 | 3 |
| serious | Anemia | Blood and lymphatic system disorders | MGD+Rituximab+Y-90-Zevalin | 0 | 2 | 0 |
| serious | Anemia | Blood and lymphatic system disorders | Rituximab+Y-90-Zevalin | 1 | 3 | 1 |
| serious | UTI | Infections and infestations | MGD+Rituximab+Y-90-Zevalin | 0 | 2 | 0 |
| serious | UTI | Infections and infestations | Rituximab+Y-90-Zevalin | 1 | 3 | 1 |
| serious | Thrombocytopenia | Investigations | MGD+Rituximab+Y-90-Zevalin | 1 | 2 | 1 |
| serious | Thrombocytopenia | Investigations | Rituximab+Y-90-Zevalin | 0 | 3 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MGD+Rituximab+Y-90-Zevalin | ||
| Total, all-cause mortality | Rituximab+Y-90-Zevalin | ||
| Total, other adverse events | MGD+Rituximab+Y-90-Zevalin | 2 | 2 |
| Total, other adverse events | Rituximab+Y-90-Zevalin | 3 | 3 |
| Total, serious adverse events | MGD+Rituximab+Y-90-Zevalin | 1 | 2 |
| Total, serious adverse events | Rituximab+Y-90-Zevalin | 2 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| MGD+Rituximab+Y-90-Zevalin vs Rituximab+Y-90-Zevalin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01549886
GET https://conductscience.org/api/trials/v1/NCT01549886/registered